The transformation of isocitrate dehydrogenase (IDH) mutations from laboratory observations to actionable therapeutic targets represents precision oncology's most remarkable clinical achievements. The contemporary Isocitrate Dehydrogenase Inhibitors Market has emerged as a fundamentally important therapeutic arena, propelled by sophisticated biological insights, transformative...